Skip to main content
. 2021 Nov 23;5(22):4783–4793. doi: 10.1182/bloodadvances.2021005117

Figure 1.

Figure 1.

Risk stratified treatment algorithm as proposed by the authors. *All the following: single mutation, <1 year of age, and normal hemoglobin F. (Low DNA methylation when testing becomes clinically available.) °Any of the following: multiple mutations, >1 year of age, or elevated hemoglobin F. (Intermediate or high DNA methylation when testing becomes clinically available.) 6-MP, 6-mercaptopurine; AZA, azacitidine.